Purpose Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment. Methods A total of 27,578 patients diagnosed with clinical stage I-IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection. Cox proportional hazards models were used to analyze survival outcomes.
Introduction
There were an estimated 74,000 new cases and 16,000 deaths from bladder cancer in the United States in 2015 [1] . Bladder cancer represents the most common urinary tract malignancy. Radical cystectomy with extended pelvic lymphadenectomy is recommended for patients with muscle-invasive bladder cancer [2] . Despite these longstanding guidelines, radical cystectomy is markedly underused; only 19-21% of patients 66 years of age and older with muscleinvasive disease are offered this potentially curative surgery [3, 4] . Patients with muscle-invasive disease have 5-year survival rates of 26-64% [5, 6] . Although the pathologic TNM classification is a durable prognostic variable, considerable heterogeneity in outcomes within stage groups has been reported [5, 6] . Taking into account the unaltered survival outcomes in bladder cancer treatment over the last three decades, [7] an aggressive approach to optimizing treatment is needed.
While bladder cancer incidence is twice as high among whites compared with blacks, there remains a disproportionately high rate of bladder cancer-specific mortality among black patients [8] . Variability in quality of care indicators such as timing to radical cystectomy, provider volume, and access to providers has been previously associated with inferior outcomes among bladder cancer patients [9] . Insurance status has also been implicated in variable access to care among cancer patients [10] . The Affordable Care Act may help mitigate this disparity by decreasing the uninsured patient population, thereby increasing access to provider services [11] . Racial/ethnic variation and utilization of radical cystectomy according to insurance status remain to be determined. Moreover, cystectomy in patients younger than 66 years of age on which healthcare reform may have a significant impact is of particular interest. We sought to characterize the utilization of radical cystectomy for patients diagnosed with bladder cancer in the United States across a wide age range.
Patients and methods

Patient population
We used Surveillance, Epidemiology, and End Results (SEER) registry data from the National Cancer Institute. We restricted our analysis to patients with bladder cancer diagnosed as transitional cell or urothelial carcinoma from 2007 through 2013. Since complete insurance information was not made available in SEER until 2007, we excluded patients prior to this date to derive our cohort. SEER data are summarized; the database contains information on patient demographics, tumor characteristics, and follow-up information. According to published guidelines on the evaluation, treatment, and surveillance of bladder cancer, most patients with muscle-invasive bladder transitional cell carcinoma should undergo radical cystectomy [2] . Patients with high-grade, recurrent of BCG refractory non-muscleinvasive bladder cancer may be offered cystectomy as a treatment option [2] . Additionally, patients with clinical T3 and T4 bladder cancer may be offered cystectomy as well, either with neoadjuvant or adjuvant chemotherapy, or as a palliative treatment option [2] The most recent release of the SEER dataset contained information on patients with newly diagnosed cancers in 18 US regions that are generalizable to the US population. Patients with bladder cancer, based on American Joint Committee on Cancer and International Union on Cancer TNM Classification and Stage groupings, were identified from the primary malignancy diagnosis codes and extentof-disease codes in the SEER database. The cancer stage identified in the SEER database conformed to the standards of the North American Association of Central Cancer Registries, and case ascertainment in the SEER data was 98% complete [12] . SEER defines stage by best pathology defined by the transurethral resection of the bladder tumor or final cystectomy specimens. Given the potential clinical staging and pathology discrepancy with the aforementioned indications for radical cystectomy, we included patients with clinical stage I-IV disease to describe utilization patterns. We specified the treatment group on the basis of the treatment codes in the SEER database. Patients who underwent radical cystectomy were identified by indicative procedure codes.
Study variables
From the SEER data, we determined patient age, race/ ethnicity (white, black, Hispanic, Asian, and other), marital status (not married, married, and unknown), clinical stage (T1, T2, T3, and T4), and SEER region (Northeast, South, Midwest, and West). We imputed subject socioeconomic status using SEER and the Area Health Resource File [13] . Education was defined according to percent of residents that have at least four years of college education. Education and income are census-derived variables at the county level. Median income was provided as an independent SEER variable. Subject age, sex, race/ethnicity, and marital status were derived from SEER demographic variables. Insurance status was defined as non-Medicaid insurance (''insured'' or insured/no specifics''), Medicaid coverage (''any Medicaid''), or uninsured. Among patients who underwent radical cystectomy, use of pelvic lymph node dissection was defined as 'yes' or 'no'. Patients who underwent pelvic lymph node dissection were grouped together by the following SEER variables 'one to three regional lymph nodes removed' and 'three or more regional lymph nodes removed' at the time of surgery.
To examine factors that are associated with undergoing radical cystectomy among patients who are newly diagnosed with bladder cancer, we created multivariable models that incorporated year of diagnosis, age, sex, race/ ethnicity, marital status, insurance status, income, education, and region. We incorporated covariates that were associated with the use of radical cystectomy in univariate models at an alpha level of 0.05 or lower into our multivariable models.
Statistical analysis
We conducted univariate analyses to assess the association of surgeries (radical cystectomy and pelvic lymph node dissection) with patient demographic variables, including age, sex, marital status, race/ethnicity, socioeconomic status (income and education), insurance status (uninsured, Medicaid coverage, or non-Medicaid insurance), and clinical characteristics, using the Pearson Chi-square test. Two multivariable logistic regression models were used to evaluate the factors associated with the use of radical cystectomy and pelvic lymph node dissection, adjusting for covariates that were clinically relevant and meaningful or had a p value less than 0.25 in the univariate analysis. Goodness of fit was assessed using the Hosmer-Lemeshow test. Cox proportional hazard models controlling for patient demographics and clinical covariates were performed to assess the relationship between the use of radical cystectomy and patients' overall survival, as well as causespecific survival. Kaplan-Meier curves were used to estimate bladder cancer-specific and overall survival according to utilization of radical cystectomy.
All statistical tests were two-sided, and all analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC). Statistical significance was defined as p \ 0.05.
Results
Patient demographics are summarized in Table 1 . Overall, 1,693 (6.1%) patients with bladder cancer underwent radical cystectomy during the study period. Patients who were younger, female, and diagnosed in more recent years of the study more often underwent radical cystectomy (all p \ 0.001). Uninsured and unmarried patients also underwent radical cystectomy more often than other groups (p \ 0.001), as did patients residing in the Midwest (p \ 0.001). Socioeconomic status (median income percentage of college education) was notably associated with increased use among the second and third quartile patients (both p \ 0.05). More advanced stage of disease was associated with increased utilization of radical cystectomy (p \ 0.001).
Factors predicting the use of radical cystectomy identified in multivariable analysis are shown in Table 2 Of the patients who underwent radical cystectomy, 1,564 (92.4%) underwent pelvic lymph node dissection at the time of surgery (Table 3) Tables 4 and  5 . In the adjusted analyses, there were significantly improved overall survival outcomes across clinical stages except for stage I disease. The greatest overall (HR 0.46, 95% CI 0.44-0.49, p \ 0.001) and cancer-specific (HR 0.45, 95% CI 0.42-0.49, p \ 0.001) survival benefit was observed for patients who underwent pelvic lymph node dissection, respectively. We used product terms of potential interaction variables in the Cox proportional hazard model to evaluate the significance of interactions between receipt of radical cystectomy and patients' demographic variables, such as sex, race/ethnicity, and insurance status, and these tests did not yield any significant interaction. 
Discussion
Although radical cystectomy is recommended in published guidelines for patients diagnosed with muscle-invasive bladder cancer, the use of this procedure is markedly limited despite evidence demonstrating inferior outcomes with alternative therapies. In the present study, we provided an analysis of recent data showing continued decreased use of radical cystectomy in patients across a wide age range and according to race/ethnicity independent of insurance status. Our study has several important findings. First, we observed only 6% of patients with muscle-invasive bladder cancer underwent a radical cystectomy. Prior studies have observed decreased utilization of radical cystectomy in up to 21% of patients [4] . We recently noted that only 19% of patients with clinical stage II disease underwent radical cystectomy [3] . While noteworthy studies, those rates were derived from an older cohort 66 years of age and older and those findings may not be applicable to a younger cohort across all clinical stages. In the present study, we provide a contemporary analysis in a larger cohort across a wide age range, thus supporting the generalizability of our findings. Interestingly, patients 51-60 years of age were not significantly associated with decreased utilization. These younger patients are most susceptible to health care reform measures which are aimed at improving outcomes among this historically underserved population. Moreover, as depicted in Figs. 1 and 2 , we observed a significantly improved survival benefit among those patients with muscle-invasive bladder cancer with the greatest benefit observed among those with clinical stage II disease. At 5 years, the survival benefit among patients with clinical stage III and IV was minimal in comparison to patients with stage II disease consistent with other reports [6] . Patients with clinical stage I non-muscle-invasive bladder cancer represent a heterogeneous population with current research efforts in identifying patients most likely to benefit from intravesical therapies versus more aggressive interventions. Thus, our findings represent a pooled cohort of these clinical stage I patients and any perceived oncologic benefit derived from radical cystectomy may be negated due to the limitations of using large cancer registry data.
Second, we found that non-Hispanic black patients were less likely to undergo radical cystectomy as well as pelvic lymph node dissection after controlling for socioeconomic and insurance status. In the univariate analyses, the nonHispanic black patients were slightly more likely to receive radical cystectomy, and this association was confounded by the fact that there were more non-Hispanic black patients diagnosed with stage IV bladder cancer than any other race/ethnicity in the study cohort. Socioeconomic status was census-derived and further individual-level assessment of income and education is needed in order to accurately assess the impact of race/ethnicity on utilization patterns. That being said, racial/ethnic disparities have been previously implicated for the decreased survival outcomes of many cancers with determinants being lower utilization of experienced providers and institutions, which provide bladder cancer surgery [9] . While we were unable to control for provider volume including distance to provider [4] as determinants for the underutilization observed, we controlled for area-level socioeconomic (income and education) and insurance status and found that being black was an independent predictor for decreased use of the procedure. Further research is needed to determine how to OR odds ratio, CI confidence interval. The variables included initially in the model selections were year of diagnosis, age group, sex, race/ ethnicity, marital status, insurance, county-level annual median household income, county-level education, % with at least 4 years of college, SEER region, and stage improve these patients' access to providers that perform radical cystectomy. Third, there was consistent and appropriate utilization of pelvic lymph node dissection at the time of radical cystectomy. Pelvic lymphadenectomy is the standard of care when performing radical cystectomy for muscle-invasive bladder cancer [2] . Prior research has suggested that variation in the use of racial cystectomy is surgeon dependent and influenced by a number of factors [4] . Reluctance to perform radical cystectomy may be related to the complexity of the procedure, increased risk of perioperative morbidity and mortality, and decreased reimbursement in recent years [4] . These factors have contributed to the centralization of care to high-volume providers for a number of complex procedures [14] . Our study demonstrated that when radical cystectomy was performed, greater than 90% of patients also underwent a pelvic lymph node dissection. This suggests that if a radical cystectomy is performed, then the vast majority of patients are appropriately undergoing a pelvic lymph node dissection. Fourth, insurance status was not a significant predictor for use of radical cystectomy. This finding has important implications for current health policy decision making aimed at improving health care through the current and potential repeal and replacement of the Affordable Care Act (ACA) [11] . Over the next 10 years, the current ACA will bring in 37 million newly insured individuals, many of which had limited access to insurance, cancer diagnosis, and treatment options as well as those with more advanced cancer [11] . Our finding suggests that merely obtaining insurance may not be enough to improve the care received, especially among younger patients. Prior research has suggested that patients with Medicaid insurance often have significant comorbid conditions and present with advanced disease which may lead to increased complications following treatment [15] . Thus, there may be an inherent selection bias among providers to limit treatment among these patients.
While our findings are policy relevant, they must be interpreted within the context of the study design. First, SEER does not record comorbidity information which may limit patients from undergoing radical cystectomy [4] . Moreover, given that there was no statistical correction for comorbidity included as a covariate, this may have influenced survival results in favor of surgery. Being an uncontrolled confounder, comorbidity status may significantly influence utilization patterns observed in the present analysis including race/ethnicity. Second, the insurance variable is relatively new to SEER and the validity of this variable has not been established [10] . In an effort to control for patients with unknown insurance status, we excluded these patients from the present study. Third, SEER does not identify providers, surgical volumes, and travel distance, which are previously recognized determinants of the quality of care and can be used to help optimize outcomes [9, 16] . Fourth, the use of perioperative chemotherapy is not recorded in SEER. However, prior research has shown that only 4% of patients with muscleinvasive bladder cancer receive neoadjuvant chemotherapy, thus potentially limiting this as a significant unmeasured confounding variable [17] . Finally, specifics regarding surgery such as anatomical extent of pelvic lymph node dissection are not captured in SEER which is an important determinant regarding surgical quality [18] . Overall survival adjusted for year, age, sex, race/ethnicity, marital status, insurance status, income, education, and region
The variables included initially in the model selections were year of diagnosis, age group, sex, race/ethnicity, marital status, insurance, county-level annual median household income, county-level education, % with at least 4 years of college, SEER region, and stage HR hazard ratio, CI confidence interval 
Conclusions
There is significant underutilization of radical cystectomy in all patients diagnosed with bladder cancer, especially among older non-Hispanic black patients. Further research evaluating how providers discuss bladder cancer and treatments as well as how patients interpret physician recommendations will be useful to elucidate disparities in bladder cancer care.
